Middle East & Africa Pharmacokinetics Services Market
No. of Pages: 88 | Report Code: BMIRE00030918 | Category: Life Sciences
No. of Pages: 88 | Report Code: BMIRE00030918 | Category: Life Sciences
The Middle East & Africa pharmacokinetics services market was valued at US$ 45.97 million in 2023 and is expected to reach US$ 74.32 million by 2031; it is estimated to register a CAGR of 6.2% from 2023 to 2031.
The growing prevalence of chronic diseases such as diabetes, cancer, and autoimmune diseases has been a prime enabler of drug development efforts across the world. According to the World Health Organization’s (WHO) 2024 data, ~422 million in the world suffer from diabetes, and these cases are mostly found in middle and low-income countries, causing approximately 1.5 million deaths every year. Pharmaceutical companies are at the forefront of developing drugs to treat various diseases. Pharmacokinetic studies are essential for understanding how these drugs behave in a patient’s body by analyzing the process of absorption, distribution, metabolization, and elimination (ADME) within the human body. The absorption of a drug into systemic circulation affects the speed and concentration at which a drug may reach the site of action, e.g., plasma. Drug distribution patterns throughout the body varies based on its biochemical properties and body physiology. Metabolism involves the processing of the drug by the body into subsequent compounds. This step is instrumental in converting the drug into water-soluble substances to render them suitable for renal clearance. Metabolism is also important for the conversion of prodrugs, such as codeine, into active metabolites. Excretion of drugs from the body is mainly governed by kidneys; however, in several cases, drugs may be excreted via the lungs, skin, or gastrointestinal tract. ADME dynamics define the bioavailability of drugs in the body, and the maintenance doses of drugs are calculated based on their clearance times (desired plasma concentration divided by bioavailability). Understanding of clearance allows practitioners to calculate appropriate dosing rates.
Pharmacokinetic studies focus on optimizing drug dose regimens in study subjects to understand the efficacy and safety of a drug. These studies are essential for ensuring the safety of drugs that are developed for long-term treatments, which helps evaluate the suitability and stability of drug formulations in chronic disease management. Hence, the rising burden of chronic and infectious diseases underlines the importance of pharmacokinetic studies to develop safe and effective personalized treatments.
South Africa accounts for the largest share of the pharmacokinetics services market in the Middle East & Africa. The government of South Africa has started providing investment incentives, taking measures to protect intellectual property (IP) rights, simplifying tax rules, and levying better regulatory policies to attract foreign investments to ultimately nurture the clinical trial landscape in the country. In 2019, a total of ~US$ 62.67 million (ZAR 1 billion) was invested in upcoming and ongoing trials. During 2016–2021, ~US$ 0.18 billion (ZAR 2.95 billion) was spent by innovative multinational pharmaceutical companies operating in South Africa to support clinical research activities focused on addressing the unmet medical needs of the country.
South Africa is the most economically developed country on the African continent, and it has established better regulatory standards for clinical trials. Lower costs of clinical research operations and a minor risk of litigation make South Africa an attractive option for foreign companies outsourcing their clinical research operations. Moreover, the number of trials has been increasing due to high recruitment rates and an improved regulatory environment in the country. South Africa receives substantial sponsorships from innovative pharmaceutical companies for conducting clinical research, with no signs of slowing down. Thus, the progressing clinical research industry bolsters the growth of the pharmacokinetics services market in the country.
Strategic insights for the Middle East & Africa Pharmacokinetics Services provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market. The geographic scope of the Middle East & Africa Pharmacokinetics Services refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.Middle East & Africa Pharmacokinetics Services Strategic Insights
Middle East & Africa Pharmacokinetics Services Report Scope
Report Attribute
Details
Market size in 2023
US$ 45.97 Million
Market Size by 2031
US$ 74.32 Million
Global CAGR (2023 - 2031)
6.2%
Historical Data
2021-2022
Forecast period
2024-2031
Segments Covered
By Drug Type
By Service Type
By End User
Regions and Countries Covered
Middle East and Africa
Market leaders and key company profiles
Middle East & Africa Pharmacokinetics Services Regional Insights
The Middle East & Africa pharmacokinetics services market is categorized into drug type, service type, therapeutic application, end user, and country.
Based on drug type, the Middle East & Africa pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held the largest market share in 2023.
In terms of service type, the Middle East & Africa pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held the largest market share in 2023.
By therapeutic application, the Middle East & Africa pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynaecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.
By end user, the Middle East & Africa pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held the largest market share in 2023.
By country, the Middle East & Africa pharmacokinetics services market is segmented into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. South Africa dominated the Middle East & Africa pharmacokinetics services market share in 2023.
Charles River Laboratories International Inc; Eurofins Scientific SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; and SGS SA are among the leading companies operating in the Middle East & Africa pharmacokinetics services market.
The Middle East & Africa Pharmacokinetics Services Market is valued at US$ 45.97 Million in 2023, it is projected to reach US$ 74.32 Million by 2031.
As per our report Middle East & Africa Pharmacokinetics Services Market, the market size is valued at US$ 45.97 Million in 2023, projecting it to reach US$ 74.32 Million by 2031. This translates to a CAGR of approximately 6.2% during the forecast period.
The Middle East & Africa Pharmacokinetics Services Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East & Africa Pharmacokinetics Services Market report:
The Middle East & Africa Pharmacokinetics Services Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East & Africa Pharmacokinetics Services Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East & Africa Pharmacokinetics Services Market value chain can benefit from the information contained in a comprehensive market report.